Share on StockTwits

Shares of Insulet (NASDAQ:PODD) have been given an average recommendation of “Buy” by the eleven ratings firms that are currently covering the stock, Stock Ratings Network reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $45.33.

PODD has been the subject of a number of recent research reports. Analysts at Canaccord Genuity cut their price target on shares of Insulet from $40.00 to $39.00 in a research note on Friday. Analysts at Barrington Research upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 15th. They now have a $40.00 price target on the stock.

In other Insulet news, CEO Duane Desisto sold 20,000 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $34.23, for a total transaction of $684,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Insulet (NASDAQ:PODD) traded up 0.77% on Monday, hitting $34.89. The stock had a trading volume of 103,340 shares. Insulet has a 1-year low of $30.04 and a 1-year high of $51.31. The stock’s 50-day moving average is $37.63 and its 200-day moving average is $40.85. The company’s market cap is $1.933 billion.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $72.94 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. Analysts expect that Insulet will post $-0.15 EPS for the current fiscal year.

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.